Amrutanjan Health Care Ltd. (BSE: 590006) is a Chennai, Tamil Nadu-based company in the Non-Prescription Drugs industry. With a market capitalisation of ₹1,482 Cr, it ranks #1,391 by market cap among the 6,137 Indian listed companies on FinBizNet, and #5 of 9 in Non-Prescription Drugs. At ₹487.65 (as of 25 Oct 2026), the share price is 35.8% below its 52-week high of ₹760.15 and 2.3% above its 52-week low of ₹476.50. The share price is down 30.3% over one year and down 4.2% over three months.
| Current Price | ₹487.65 |
|---|---|
| Market Cap | ₹1,482 Cr |
| BSE Code | 590006 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 25.6 |
| Return on Equity | 16.62% |
| Return on Assets | 8.47% |
| 52-Week Range | ₹476.50 – ₹760.15 |
| 1-Year Price Change | -30.3% |
| 3-Month Price Change | -4.2% |
| Beta (1Y) | 0.09 |
| Dividend Yield | 1.70% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.amrutanjan.com |
| Revenue | ₹103 Cr |
|---|---|
| Net Profit | ₹4 Cr |
| Net Margin | 4.2% |
| EPS (Basic) | ₹1.51 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms brand name; and fruit and rehydration juice drinks under the Fruitnik brand name. The company also offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints, as well as provides sanitary napkins for women. In addition, it operates a pain management center. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.
1. OTC Products-This segment manufactures over the counter products related to pain management, congestion management, and hygiene. 2. Beverages-This segment produces fruit juices and oral rehydration drinks. 3. Others-This segment operates pain management center. 4. Unallocated Assets-0
1. Others-0.6% 2. Beverages-6.3% 3. OTC Products (Excl. Women Hygiene)-65.3% 4. Women's Hygiene & Personal Care-27.8%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd. | ₹43,456 Cr | 40.8 | 48.91% | ₹938 Cr | -11.7% |
| Alembic Pharmaceuticals Limited (Aplltd) | ₹15,518 Cr | 23 | 12.36% | ₹2,150 Cr | -18.6% |
| Bliss Gvs Pharma Ltd. | ₹7,005 Cr | 52.5 | 11.60% | ₹286 Cr | +308.7% |
| Zota Health Care Ltd | ₹4,881 Cr | -60.3 | -16.05% | ₹174 Cr | -17.5% |
| Amrutanjan Health Care Ltd. | ₹1,482 Cr | 25.6 | 16.62% | ₹103 Cr | -30.3% |
| Jenburkt Pharmaceuticals Ltd. | ₹404 Cr | 11.7 | 18.84% | — | -11.8% |
| Sat Kartar Life Limited | ₹210 Cr | 12.3 | — | — | — |
| Vista Pharmaceuticals Ltd. | ₹39 Cr | -7.9 | -10.82% | — | -37.7% |
| Welcure Drugs & Pharmaceuticals | ₹25 Cr | -5 | -5.50% | — | -75.6% |
Listed by market capitalisation. Ratios are shown for context only.
Amrutanjan Health Care Ltd. is trading at ₹487.65, with a market capitalisation of ₹1,482 Cr.
Amrutanjan Health Care Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Amrutanjan Health Care Ltd. has a P/E of 25.6 and a return on equity of 16.62%.
Amrutanjan Health Care Ltd. is listed on the BSE under the scrip code 590006.
Amrutanjan Health Care Ltd.'s share price is down 30.3% over one year and down 4.2% over three months. Its 52-week range is ₹476.50 to ₹760.15.
In Q1 FY27, Amrutanjan Health Care Ltd. reported revenue of ₹103 Cr and net profit of ₹4 Cr, with basic EPS of ₹1.51 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.